1. Home
  2. CLSK vs WGS Comparison

CLSK vs WGS Comparison

Compare CLSK & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CleanSpark Inc.

CLSK

CleanSpark Inc.

N/A

Current Price

$8.09

Market Cap

3.1B

Sector

Finance

ML Signal

N/A

Logo GeneDx Holdings Corp.

WGS

GeneDx Holdings Corp.

N/A

Current Price

$69.04

Market Cap

2.7B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
CLSK
WGS
Founded
1987
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Retail: Computer Software & Peripheral Equipment
Sector
Finance
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
2.7B
IPO Year
2008
2020

Fundamental Metrics

Financial Performance
Metric
CLSK
WGS
Price
$8.09
$69.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
8
Target Price
$21.87
★ $93.50
AVG Volume (30 Days)
★ 14.8M
732.9K
Earning Date
11-24-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 62.37
EPS
★ N/A
N/A
Revenue
★ $766,314,000.00
$427,539,000.00
Revenue This Year
N/A
$12.70
Revenue Next Year
$3.51
$24.31
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 102.21
39.97
52 Week Low
$7.06
$32.21
52 Week High
$19.17
$170.87

Technical Indicators

Market Signals
Indicator
CLSK
WGS
Relative Strength Index (RSI) 33.97 46.70
Support Level N/A $56.09
Resistance Level $10.62 $73.04
Average True Range (ATR) 0.66 5.62
MACD -0.00 0.86
Stochastic Oscillator 27.22 66.61

Price Performance

Historical Comparison
CLSK
WGS

About CLSK CleanSpark Inc.

Cleanspark Inc. is a data center developer that, until recently, focused exclusively on bitcoin mining. The company provides scalable, energy-efficient digital infrastructure across the United States. The Company has a sole reporting segment, which is the bitcoin mining segment.

About WGS GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Share on Social Networks: